Quick Answer
SANGAMO THERAPEUTICS, INC reported Cash And Cash Equivalents At Carrying Value of $20.95 million for the year ending 2025.
- SANGAMO THERAPEUTICS, INC showed a decrease of -50.0% in Cash And Cash Equivalents At Carrying Value from 2024 to 2025.
- This data is from SANGAMO THERAPEUTICS, INC's annual report (Form 10-K), filed with the SEC on March 30, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2010: $10.78 million | Q1 2011: $6.88 million | Q2 2011: $8.42 million | Q3 2011: $21.67 million | Q1 2012: $24.49 million | Q2 2012: $18.48 million | Q3 2012: $13.72 million | Q1 2013: $12.18 million | Q2 2013: $12.05 million | Q3 2013: $80.31 million | Q1 2014: $126.82 million | Q2 2014: $99.27 million | Q3 2014: $11.21 million | Q1 2015: $25.26 million | Q2 2015: $10.77 million | Q3 2015: $34.29 million | Q1 2016: $33.01 million | Q2 2016: $12.96 million | Q3 2016: $27.99 million | Q1 2017: $18.49 million | Q2 2017: $69.84 million | Q3 2017: $29.89 million | Q4 2017: $49.83 million | Q1 2018: $30.71 million | Q2 2018: $59.41 million | Q3 2018: $39.30 million | Q4 2018: $140.42 million | Q1 2019: $80.97 million | Q2 2019: $169.22 million | Q3 2019: $114.29 million | Q4 2019: $80.43 million | Q1 2020: $85.75 million | Q2 2020: $467.44 million | Q3 2020: $259.39 million | Q4 2020: $131.33 million | Q1 2021: $122.98 million | Q2 2021: $169.88 million | Q3 2021: $176.95 million | Q4 2021: $178.87 million | Q1 2022: $120.26 million | Q2 2022: $117.71 million | Q3 2022: $94.57 million | Q4 2022: $100.44 million | Q1 2023: $78.24 million | Q2 2023: $66.83 million | Q3 2023: $56.51 million | Q4 2023: $45.20 million | Q1 2024: $54.42 million | Q2 2024: $27.79 million | Q3 2024: $39.20 million | Q1 2025: $25.18 million | Q2 2025: $38.34 million | Q3 2025: $29.62 million.
- Over the full 18 years of available data (2008 to 2025), SANGAMO THERAPEUTICS, INC's Cash And Cash Equivalents At Carrying Value has grown by 7.9%.
- Historical annual values: Fiscal year 2025: $20.95 million | Fiscal year 2024: $41.92 million | Fiscal year 2023: $45.20 million | Fiscal year 2022: $100.44 million | Fiscal year 2021: $178.87 million | Fiscal year 2020: $131.33 million | Fiscal year 2019: $80.43 million | Fiscal year 2018: $140.42 million | Fiscal year 2017: $49.83 million | Fiscal year 2016: $22.06 million | Fiscal year 2015: $69.48 million | Fiscal year 2014: $6.03 million | Fiscal year 2013: $10.19 million | Fiscal year 2012: $21.68 million | Fiscal year 2011: $16.77 million | Fiscal year 2010: $10.78 million | Fiscal year 2009: $21.16 million | Fiscal year 2008: $19.41 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: